OBR Daily Commentary

forumImage

FDA Warns Companies To Stop Making ‘Unsubstantiated’ Claims About CBD Curing Cancer And Alzheimer’s

(MarketWatch) Apr 7, 2019 - Warning letters from the FTC and FDA come ahead of a public hearing on the increasingly popular additive. Federal regulators cautioned three companies to stop making their “unsubstantiated advertising claims” on all the alleged benefits of CBD products, ranging from oils to soft gels to gummies. The joint warning letters from the Food & Drug Administration and the Federal Trade Commission urged the three companies to rethink how they presented their products online and in social media posts. The warning letters were dated March 28, but announced Tuesday.

Read Article arrow

Howard S. Hochster, MD (Posted: April 08, 2019)

quotesThanks to the FDA for this initiative. Underscoring once again that there is nothing "medical" about "medical marijuana," those seeking financial benefit have turned CBD into 21st century snake oil. Claims of its benefit far exceed the small amount of medical evidence for seizures and are based on anecdotal evidence. We need appropriately conducted controlled clinical trials to determine the medical benefits of both marijuana and CBD. Government support and lowering of barriers to conducting this research are necessary. quotes

Add Comment 1 Comment
forumImage

Death By 1,000 Clicks: Where Electronic Health Records Went Wrong

(KHN/Fortune) Mar 18, 2019 - The U.S. government claimed that turning American medical charts into electronic records would make health care better, safer and cheaper. Ten years and $36 billion later, the system is an unholy mess. Inside a digital revolution that took a bad turn.

Read Article arrow

Howard S. Hochster, MD (Posted: March 19, 2019)

quotesThis amazing article should be required reading for all physicians and healthcare administrators. The article explains why all the EHRs are essentially modified billing systems that do not serve the physicians or patients. Every physician spends many uncompensated hours doing notes at home in the evenings and weekends. This is an abuse and is a major factor in burnout. #takebackourtimequotes

Add Comment 1 Comment
forumImage

Lynparza Significantly Delayed Disease Progression As 1st-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer

(AstraZeneca) Feb 26, 2019 - AstraZeneca and MSD Inc., Kenilworth, N.J., US today announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) vs. placebo. The safety and tolerability profile of Lynparza was consistent with previous trials. POLO is a randomised, double-blinded, placebo-controlled trial exploring the efficacy of Lynparza tablets as 1st-line maintenance monotherapy in patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease has not progressed on platinum-based chemotherapy.

Read Article arrow

Howard S. Hochster, MD (Posted: February 27, 2019)

quotesGreat news for patients with BRCA mutation-related pancreatic cancer. Olaparib maintenance after induction with platinum-based chemotherapy extends time to disease progression (and hopefully, survival). This important study denostrates two key points: 1. Platinum based chemo sensitivity is a marker for PARP inhibitor activity and 2. Patients with BRCA mutation-related pancreatic cancer also can benefit from this class of drugs (previously shown active in breast and ovarian cancers). We now appreciate that BRCA biology is more similar across diseases than different.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...